Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ESH CLL 2022 | CLL treatment: a look into the future

John Allan • 16 Mar 2022
ESH CLL 2022
Chronic Lymphocytic Leukemia Leukemia

John Allan, MD, Weill Cornell Medicine, New York, NY, discusses the future of chronic lymphocytic leukemia (CLL) treatment, drawing focus on the excitement around moving towards fixed-duration, chemotherapy-free oral regimens and novel agents. Dr Allan also mentions the promise of Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors in the future of CLL treatment, and the importance of tailoring therapies based on a patient’s risk factors, comorbidities and disease biology. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

Disclosures

(Consultancy: Abbvie, AstraZenenca, BeiGene, Genentech, Janssen, Pharmacyclics) Research Genentech, Janssen

More from John Allan

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax 2:43
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
John Allan • 12 Oct 2023
BruVenG trial: zanubrutinib and venetoclax, with obinutuzumab consolidation following MRD-positivity 3:15
BruVenG trial: zanubrutinib and venetoclax, with obinutuzumab consolidation following MRD-positivity
John Allan • 12 Oct 2023
Combining BTK and BCL-2 inhibitors for the treatment of CLL 1:26
Combining BTK and BCL-2 inhibitors for the treatment of CLL
John Allan • 16 Mar 2022
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation 2:07
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
John Allan • 16 Mar 2022

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals